M

Mersana Therapeutics
D

MRSN

0.35270
USD
-0.03
(-7.57%)
مغلق
حجم التداول
102,728
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
43,957,473
أصول ذات صلة
AMGN
AMGN
-0.04
(-0.01%)
271.89 USD
C
CRSP
-0.760
(-2.02%)
36.850 USD
E
EDIT
-0.07000
(-4.32%)
1.55000 USD
INCY
INCY
-0.250
(-0.39%)
64.250 USD
N
NKTR
0.00400
(0.62%)
0.64810 USD
REGN
REGN
-8.04
(-1.35%)
588.61 USD
المزيد
الأخبار المقالات

العنوان: Mersana Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADCplatforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.